Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 14/20 | 0.61 |
| ▸ | CTSL | P07711 | 4/20 | 0.54 |
| ▸ | CTSB | P07858 | 2/20 | 0.54 |
| ▸ | TACR1 | P25103 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 3/20 | 0.53 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4676446 | 0.89 | CTSK (0.66) | CTSKCTSLCTSBTACR1CTSS | |
| SCHEMBL4674921 | 0.88 | CTSK (0.65) | CTSKCTSLCTSBCTSS | |
| SCHEMBL4674918 | 0.88 | CTSK (0.65) | CTSKCTSLCTSBCTSS | |
| SCHEMBL6355820 | 0.83 | CTSK (0.64) | CTSKCTSLCTSBTACR1CTSS | |
| SCHEMBL6360120 | 0.83 | CTSK (0.66) | CTSKCTSLCTSBTACR1CTSS | |
| SCHEMBL6353434 | 0.82 | CTSK (0.65) | CTSKCTSLCTSBTACR1CTSS | |
| SCHEMBL6355803 | 0.80 | CTSK (0.62) | CTSKCTSLCTSBCTSSCAPN1 | |
| SCHEMBL4678828 | 0.80 | CTSK (0.61) | CTSKCTSLCTSBTACR1CTSS | |
| SCHEMBL4678825 | 0.80 | CTSK (0.61) | CTSKCTSLCTSBTACR1CTSS | |
| SCHEMBL4678780 | 0.78 | CTSK (0.66) | CTSKCTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050154048-A1 | Novel acyl hydrazino thiophene derivatives, process for preparing them, their use as medicinal products, pharmaceutical compositions and novel use | AVENTIS PHARMA S.A. (FR) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154048-A1 | Novel acyl hydrazino thiophene derivatives, process for preparing them, their use as medicinal products, pharmaceutical compositions and novel use | CTSZ, CTSE, CTSS | CTSK 8/4885CTSL 17/4885CTSB 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.